Firstsource named a 'Star Performer' and a 'Major Contender' in Everest Group's Financial Crime and Compliance (FCC) Operations Services PEAK Matrix® Assessment 2025
Everest Group recognized Firstsource for its strong UK presence, expanded scope from fraud specialization to end-to-end FCC operations, and its AI-powered, BPaaS-led delivery model. The Star Performer distinction, awarded selectively to providers demonstrating the most substantial year-on-year progress, underscores the success of Firstsource's differentiated UnBPO™ strategy in reshaping FCC delivery.
Vivek Sharma, Head – BFS, CMT, and Emerging Geos, Firstsource, shared, 'Being named both a Major Contender and a Star Performer by Everest Group is strong validation of our strategy to build one of the most agile and future-ready FCC delivery models in the industry. The Star Performer distinction, especially, reflects the pace and quality of our progress. Through our UnBPO™ approach, we're blending deep domain expertise with GenAI and Agentic AI to help financial institutions detect, investigate, and respond to financial crime – faster, smarter, and with greater personalization. In the US, we're seeing strong momentum as more financial institutions choose us as their partner for scalable, AI-powered compliance – a clear signal that we're solving for today while building for what's next.'
Dheeraj Maken, Practice Director, Everest Group, shared, 'As buyers look for delivery partners that balance operational scale with targeted technology investments, Firstsource offers a geographically distributed FCC delivery model combined with gradual gen AI adoption.
Firstsource has invested in modular AI tools such as Firstsource relAI™ and Analyst Co-Pilot, alongside training initiatives through the Firstsource Academy to enhance its capabilities in alert handling, QA automation, and investigation workflows. These elements have contributed to its recognition as a Major Contender and Star Performer in our Financial Crime and Compliance (FCC) Operations Services PEAK Matrix® Assessment 2025.'
Key highlights from the report:
AI-powered BPaaS model: Firstsource has evolved its BPaaS offering, initially anchored by the Muimos partnership, into a flexible and scalable platform that delivers end-to-end FCC coverage across AML, KYC, and fraud.
Future-ready workforce through FCC Academy: With GenAI-powered skilling solutions such as AI Coach and automation-led QA, the FCC Academy is accelerating analyst readiness and setting new benchmarks for professional FCC delivery.
Operational impact through modular AI and automation: Investments in solutions like Firstsource relAI™, Analyst Co-Pilot, and Digital Cockpit are reducing false positives, improving alert accuracy, and expediting fraud and AML investigations.
Balanced global presence: Building on its strong UK foundation, Firstsource is actively expanding FCC delivery capabilities in North America while leveraging offshore, nearshore, and client-site operations to provide scale, resilience, and regulatory alignment.
To download a copy of the report, please visit: https://www.firstsource.com/about/analyst-recognitions/everest-fcc-peak-matrix-2025-recognition
About Everest Group
Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.
About Firstsource
Firstsource Solutions Limited, an RP-Sanjiv Goenka Group company (NSE: FSL) (BSE: 532809) (Reuters: FISO.BO) (Bloomberg: FSOL:IN), is a global leader providing business process solutions and services spanning the customer lifecycle across Healthcare, Banking and Financial Services, Communications, Media and Technology, Retail, and other diverse industries. With a global footprint across US, UK, India, Philippines, Mexico, Romania, Turkey, Trinidad & Tobago, South Africa, and Australia, we 'make it happen' for our clients, solving their biggest challenges with hyper-focused, domain-centered teams and cutting-edge tech, data, and analytics. Our inch-wide, mile-deep practitioners work collaboratively, leveraging UnBPO™ – our differentiated approach to reimagining traditional outsourcing – to deliver real-world, future-focused solutions that drive speed, scale, and smarter decision, turning transformation into tangible results for our clients. (www.firstsource.com)
DisclaimerLicensed extracts taken from Everest Group's PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group's PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group's analysts and included in Everest Group's PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.
Photo: https://mma.prnewswire.com/media/2748790/Firstsource_Everest_Group.jpgLogo: https://mma.prnewswire.com/media/2515360/Firstsource_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/firstsource-named-a-star-performer-and-a-major-contender-in-everest-groups-financial-crime-and-compliance-fcc-operations-services-peak-matrix-assessment-2025-302527806.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
Conformal Medical Closes $32 Million Series D Extension to Advance its Next-Generation Left Atrial Appendage Occlusion Technology
New partner reinforces confidence in the company's progress and future potential. NASHUA, N.H., Aug. 12, 2025 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, announced the successful closing of its Series D extension financing, with a new partner joining inside investors to raise a total of $32 million. The funds will support the enrollment of the company's ongoing CONFORM Pivotal Trial and fund key pre-commercialization initiatives for CLAAS® AcuFORM™ LAAO system. The CONFORM Pivotal Trial is the company's clinical trial evaluating the safety and efficacy of the CLAAS® System compared to other commercially available LAAO devices and will support U.S. Food and Drug Administration (FDA) pre-market approval. The CLAAS AcuFORM System is designed to seal the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib) to reduce the risk of stroke without the need for anticoagulants. 'We are pleased to have treated over 100 patients with the next-generation AcuFORM™ System, with impressive deliverability and safety performance to date,' said James Reinstein, President and CEO of Conformal Medical. 'We look forward to building upon this robust body of evidence to further validate our one-size strategy, and the promising experience from our GLACE trial, demonstrating successful use of ICE guidance as it would eliminate the need for general anesthesia and intubation for these procedures.' Conformal Medical's proprietary CLAAS AcuFORM technology features a foam-based architecture designed to conform to a broad range of LAA anatomies with only two sizes. The AcuFORM device may also accelerate the shift to ICE-guided LAAO closure due to simplified sizing and seal confirmation, thereby potentially eliminating the need for a procedural transesophageal echocardiogram and general anesthesia. This is a significant advancement with the potential to shift clinical practice to a single-operator procedure that is less invasive for patients. The company remains focused on completing the CONFORM and GLACE clinical trials to demonstrate its safety profile and ability to offer breakthrough solutions that address unmet clinical needs and transform the way Left Atrial Appendage Occlusion is treated. Piper Sandler acted as exclusive financial advisor, and Gunderson Dettmer acted as legal counsel to Conformal Medical in this transaction. About CONFORM Pivotal Trial The CONFORM Pivotal Trial is a prospective, multicenter, randomized controlled study evaluating the safety and efficacy of the Conformal CLAAS AcuFORM System compared to other commercially available left atrial appendage (LAA) devices. The trial plans to randomize approximately 1,600 patients at sites worldwide and is now >30% enrolled. It aims to generate pivotal data supporting next-generation stroke prevention therapies for individuals with non-valvular atrial fibrillation (AFib) who are seeking an alternative to long-term oral anticoagulation. For more information, visit About Conformal Medical Conformal Medical, Inc. is a medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology is intended to make left atrial appendage closure a same-day, single-operator procedure. For more information, visit CAUTION: Investigational Device. The CLAAS System is limited by Federal (or United States) law to investigational use.
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Copan Launches UriVerse™: Fully Automated Solution for Urine Specimen Aliquoting
MURRIETA, Calif., Aug. 12, 2025 /PRNewswire/ — Copan, a leader in microbiology laboratory and automation innovations, proudly announced the official launch of UriVerse™ during the Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo in Chicago, IL. UriVerse is a state-of-the-art, fully automated system that transforms the pre-analytical handling of urine specimens by automating key manual steps. UriVerse automates critical steps including de-capping, barcode labeling, aliquoting, and re-capping which helps laboratories reduce manual labor and minimize errors. Revolutionizing Urine Specimen Workflow Urine specimens constitute a significant portion of the laboratory's daily workload, yet key pre-analytical steps like aliquoting are often still performed manually. UriVerse can reduce hands-on time, minimize errors, and help laboratories handle growing urine volumes with greater efficiency and consistency. UriVerse eliminates manual pipetting and sorting with continuous, random-access loading, cup recognition, and automated aliquoting, labeling and capping, all in one platform. A Unique System for Urine Specimen Aliquoting 'Copan continues to pioneer technologies that support the advancement of laboratory automation,' said Fabrizio Mazzocchi, CEO of Copan Diagnostics. 'With UriVerse, we offer an efficient, accurate solution to help laboratories meet rising urine testing demands, particularly in chemistry and toxicology, while reducing variability through the automation of manual pre-analytical tasks.' UriVerse is designed to address the challenges of modern urine testing workflows, especially in laboratories facing increasing volume, limited personnel, and rising expectations for faster turnaround time. By automating these manual processes, UriVerse supports better specimen traceability and fits easily into existing laboratory workflows. UriVerse Now Available in the U.S. Following its successful debut at ADLM, UriVerse is now available in the United States directly through Copan Diagnostics. The new instrument joins Copan's renowned portfolio of automation solutions, including WASP® and WASPLab®, reinforcing the company's commitment to innovation in specimen collection, transport, and pre-analytical automation. About Copan Diagnostics, Inc. Copan Diagnostics is part of Copan Group, a leading global manufacturer of collection and transport systems. Through its collaborative approach, Copan has developed breakthrough technologies such as FLOQSwabs®, ESwab®, UTM® Universal Transport Medium™, and full laboratory automation and artificial intelligence. Copan continues to innovate and transform collection and transport systems, as well as laboratory automation, assisting healthcare providers to improve patient care. For more information, visit
Malaysian Reserve
4 hours ago
- Malaysian Reserve
RepTrak Appoints Thierry D'Hers and Catherine Hernandez-Blades to Board of Directors
BOSTON, Aug. 12, 2025 /PRNewswire/ –The RepTrak Company™, the world's leading provider of reputation intelligence, proudly announces the appointment of Thierry D'Hers and Catherine Hernandez-Blades to its Board of Directors. These strategic appointments underscore RepTrak's commitment to scaling its reputation intelligence suite with cutting-edge technologies, AI-driven insights, and product innovation. Thierry D'Hers Thierry D'Hers brings more than two decades of experience in product innovation, engineering leadership, and advisory roles. He is most known for his foundational role at Tableau, where he helped scale the company's data visualization platform, PowerBI, into a global business intelligence leader. Most recently, he served as Chief Product & Engineering Officer at Vivun. D'Hers has also advised several tech organizations including Pigment, Radar, Indico Labs, and Headwaters Economics — holding strategic roles in both enterprise and mission-driven technology ventures. 'RepTrak is uniquely positioned at the intersection of technology, data, and trust,' said D'Hers. 'I'm excited to join the Board at a time when innovation and AI are reshaping how organizations manage stakeholder perception. I look forward to aiding the growth of the world's most powerful reputation intelligence platform.' Catherine Hernandez-Blades Catherine Hernandez-Blades holds a distinguished track record across the financial services, defense, aerospace, technology, and government sectors. She currently serves as an independent board director for CoreCivic, Inc., where she sits on the Nominating & Governance and Risk Committees. Previously, she held C-suite roles at three Fortune 500 companies: Chief Marketing and Communications Officer at SAIC, Aflac, and Flex. In addition, she is an EMMY® winner, Cannes Lions recipient, Forbes Top 50 Global CMO, and the first and only American recipient of the Relations 4 the Future medal at Davos. 'Having relied on RepTrak's products and services for over a decade across multiple Fortune 500 companies, I can personally attest to the platform's immense value. It not only quantifies the business impact driven by teams but also plays a crucial role in strategic decision-making — extending its influence to the entire C-suite and Board of Directors. I'm particularly excited about the innovative new products in development and am delighted to join RepTrak's board.' Fueling Product and Platform Evolution These appointments reflect a deliberate move to accelerate the evolution of RepTrak's recently launched platform, Compass™ — deepening its technology, product, governance, and communications expertise. D'Hers and Hernandez-Blades bring strengths that will help guide RepTrak through its next phase of growth and innovation. 'Thierry and Catherine bring distinct and deeply aligned expertise to RepTrak. Thierry's product and AI leadership, paired with Catherine's global reputation leadership, governance insight, and ESG acumen, position us to serve clients with sharper intelligence, deeper trust, and greater value than ever before. We are proud to welcome them both to the Board' says Mark Sonders, CEO of The RepTrak Company. About The RepTrak Company The RepTrak Company is the world's premier provider of reputation data and insights, helping businesses harness reputation intelligence to secure competitive advantage. RepTrak's predictive insights enable subscribers to safeguard business value, optimize ROI, and amplify their positive societal impact. Combining advanced metrics with dedicated reputation advisors, RepTrak delivers actionable analyses that align business goals with stakeholder sentiment across global markets and diverse industries. Established in 2004, The RepTrak Company owns the world's largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit About RepTrak Compass Compass is the only truly integrated global solution for reputation intelligence — combining RepTrak's world-class Global Advisory expertise with AI-enabled navigation. Designed for today's dynamic stakeholder environment, Compass enables leaders to shift from measuring reputation to actively shaping it. RepTrak invites communications, corporate affairs, brand, and reputation leaders around the world to explore Compass — and see how it empowers them to lead reputation, not just report on it. To learn more about Compass, visit
